The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift ...

Background Remission and low-disease activity are recommended targets in systemic lupus erythematosus (SLE), yet many ...